Candel Therapeutics (NASDAQ:CADL) vs. Gossamer Bio (NASDAQ:GOSS) Financial Contrast

Candel Therapeutics (NASDAQ:CADL) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Volatility and Risk

Candel Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.

Institutional and Insider Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Candel Therapeutics and Gossamer Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1	2	7	0	2.60
Gossamer Bio	2	3	4	0	2.22

Candel Therapeutics presently has a consensus price target of $18.57, indicating a potential upside of 75.53%. Gossamer Bio has a consensus price target of $3.20, indicating a potential upside of 1,693.72%. Given Gossamer Bio’s higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Candel Therapeutics.

Valuation and Earnings

This table compares Candel Therapeutics and Gossamer Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18 million	($0.98)	-10.80
Gossamer Bio	$48.47 million	0.86	-$170.37 million	($0.79)	-0.23

Candel Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Candel Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Candel Therapeutics and Gossamer Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Gossamer Bio	-324.82%	N/A	-96.10%

Summary

Gossamer Bio beats Candel Therapeutics on 7 of the 13 factors compared between the two stocks.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.